Clinical measures in transthyretin familial amyloid polyneuropathy

被引：53
|
作者：
Coelho, Teresa [1 ]
Vinik, Aaron [2 ]
Vinik, Etta J. [2 ]
Tripp, Tara [3 ]
Packman, Jeff [4 ]
Grogan, Donna R. [4 ]
机构：
[1] Hosp Santo Antonio, Ctr Hosp Porto, P-4099001 Oporto, Portugal
[2] Eastern Virginia Med Sch, Strelitz Diabet Ctr, Norfolk, VA 23501 USA
[3] DM Stat Inc, Malden, MA USA
[4] FoldRx Pharmaceut Inc, Cambridge, MA USA
来源：
MUSCLE & NERVE | 2017年 / 55卷 / 03期
关键词：
amyloidosis; modified body mass index; nerve fiber function; Neuropathy Impairment Score; Norfolk Quality of Life; ROCHESTER DIABETIC-NEUROPATHY; RETINOL-BINDING-PROTEIN; LIVER-TRANSPLANTATION; FOLLOW-UP; PERIPHERAL NEUROPATHY; END-POINTS; TAFAMIDIS; SURVIVAL; TRIAL; DYSFUNCTION;
D O I：
10.1002/mus.25257
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IntroductionThis observational, cross-sectional, single-center study aimed to identify instruments capable of measuring disease progression in transthyretin familial amyloid polyneuropathy (TTR-FAP). MethodsThe relationship between disease stage and Neuropathy Impairment Score-Lower Limbs (NIS-LL) and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score was assessed in 61 (stages 1-3) patients with TTR-FAP (V30M variant) and 16 healthy controls. Composite measures of large- and small-nerve fiber function, and modified body mass index (mBMI) were also assessed. ResultsOrdinal-based NIS-LL and Norfolk QOL-DN scores discriminated between disease stages (P<0.0001 for NIS-LL and Norfolk QOL-DN). Longer disease duration correlated with worse NIS-LL and Norfolk QOL-DN. Karnofsky performance score declined progressively by disease stage. Composite measures of nerve fiber function differentiated stage 1 from stage 2 disease. The mBMI declined with advancing disease. ConclusionsNIS-LL, Norfolk QOL-DN score, composite endpoints of nerve fiber function, and mBMI are valid, reliable measures of TTR-FAP severity. Muscle Nerve55: 323-332, 2017
引用
收藏
页码：323 / 332
页数：10
相关论文
共 50 条
  • [1] Outcome Measures for Transthyretin Type Familial Amyloid Polyneuropathy
    Coehlo, Teresa
    Merkies, Ingemar
    Vinik, Aaron
    Vinik, Etta J.
    Chan, Jason
    Packman, Jeff
    Grogan, Donna R.
    NEUROLOGY, 2010, 74 (09) : A336 - A336
  • [2] PREALBUMIN (TRANSTHYRETIN) IN FAMILIAL AMYLOID POLYNEUROPATHY
    KOEPPEN, AH
    MITZEN, EJ
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1984, 43 (03): : 303 - 303
  • [3] Transthyretin familial amyloid polyneuropathy: an update
    Violaine Plante-Bordeneuve
    Journal of Neurology, 2018, 265 : 976 - 983
  • [4] Transthyretin familial amyloid polyneuropathy: an update
    Plante-Bordeneuve, Violaine
    JOURNAL OF NEUROLOGY, 2018, 265 (04) : 976 - 983
  • [5] Transthyretin related familial amyloid polyneuropathy
    Planté-Bordeneuve, V
    Said, G
    CURRENT OPINION IN NEUROLOGY, 2000, 13 (05) : 569 - 573
  • [6] REHABILITATION OF PATIENTS WITH TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
    Theaudin, M.
    Adams, D.
    De Sousa, A.
    Lemoine, C.
    Morier, A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 305 - 305
  • [7] The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
    Agnès Morier
    Alyssa De Sousa
    Colombe Lemoine
    Cecile Cauquil
    Marie Théaudin
    David Adams
    Hervé Chanut
    Orphanet Journal of Rare Diseases, 10 (Suppl 1)
  • [8] PREVALENCE OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY IN PORTUGAL
    Ines, M.
    Coelho, T.
    Conceicao, I
    Duarte-Ramos, F.
    Carvalho, M.
    Costa, J.
    VALUE IN HEALTH, 2015, 18 (07) : A662 - A662
  • [9] Cutaneous Manifestations of Familial Transthyretin Amyloid Polyneuropathy
    Lanoue, Julien
    Wei, Nancy
    Gorevic, Peter
    Phelps, Robert G.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2016, 38 (10) : 719 - 725
  • [10] ECONOMIC BURDEN OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
    Ines, M.
    Coelho, T.
    Conceicao, I
    Landeiro, F.
    Borges, M.
    Carvalho, M.
    Costa, J.
    VALUE IN HEALTH, 2018, 21 : S451 - S451
12345